NGL Fine-Chem Limited (BOM:524774)

Market Cap	9.33B
Revenue (ttm)	4.08B
Net Income (ttm)	209.59M
Shares Out	6.18M
EPS (ttm)	33.82
PE Ratio	44.65
Forward PE	n/a
Dividend	1.75 (0.11%)
Ex-Dividend Date	Aug 12, 2025

Volume	66
Average Volume	103
Open	1,561.00
Previous Close	1,505.20
Day's Range	1,549.45 - 1,580.00
52-Week Range	962.70 - 2,031.05
Beta	0.30
RSI	66.58
Earnings Date	Feb 3, 2026

About NGL Fine-Chem

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltra...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1981
• Employees: 520
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524774

Financial Performance

In 2024, NGL Fine-Chem's revenue was 3.68 billion, an increase of 8.73% compared to the previous year's 3.39 billion. Earnings were 211.24 million, a decrease of -48.87%.